Aardvark Therapeutics (AARD) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Immunic (IMUX) has outperformed Aardvark Therapeutics (AARD) over the past year, losing 15.8% versus a loss of 72.5%. Immunic is the larger company by market cap ($111.7 million vs $104.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AARD | IMUX |
|---|---|---|
| Share price | $4.76 | $8.19 |
| Market cap | $104.17M | $111.75M |
| 1-day change | +1.06% | +8.33% |
| YTD return | -64.11% | +41.57% |
| 1-year return | -72.50% | -15.81% |
| 5-year return | — | -91.28% |
| EPS (TTM) | $-3.21 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $17.06 | $17.43 |
| 52-week low | $3.35 | $5.06 |
| Distance from 52-week high | -72.09% | -53.01% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +133.40% | +426.13% |
| Average volume | 208.11K | 284.68K |
| Shares outstanding | 21.88M | 13.64M |
| Employees | 28 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed AARD by 56.7 percentage points over the past year.
About Aardvark Therapeutics
AARD stock →Aardvark Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. Aardvark Therapeutics, Inc.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
AARD vs IMUX FAQ
Which is bigger, Aardvark Therapeutics or Immunic?
Immunic (IMUX) is larger, with a market capitalization of $111.75M compared with $104.17M for Aardvark Therapeutics (AARD).
Which stock has performed better over the past year, AARD or IMUX?
IMUX returned -15.81% over the past 12 months, compared with -72.50% for AARD (price return, excluding dividends). Past performance does not predict future results.
Are Aardvark Therapeutics and Immunic in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.